Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Xencor Inc XNCR

Healthcare Biotechnology
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of... see more

Recent & Breaking News (NDAQ:XNCR)

Xencor Reports First Quarter 2014 Financial Results

PR Newswire May 14, 2014

Xencor to Host First Quarter 2014 Financial Results Webcast and Conference Call

PR Newswire May 7, 2014

Xencor, Inc. to Present at Deutsche Bank 39th Annual Health Care Conference

PR Newswire April 29, 2014

Xencor Receives Milestone Payment from Merck for Initiation of Phase 1 Clinical Trial of a Biologic Candidate using XmAb® Antibody Engineering Intellectual Property

PR Newswire April 10, 2014

Xencor Showcases Bispecific Antibody Programs at Annual Summit on Practical and Emerging Trends in Multiple Myeloma

PR Newswire March 28, 2014

Xencor to Present at 21st Annual BioCentury Future Leaders in the Biotech Industry Conference

PR Newswire March 24, 2014

Xencor Reports Fourth Quarter and Full Year 2013 Financial Results

PR Newswire March 19, 2014

Xencor, Inc. to Host Fourth Quarter and Full Year 2013 Financial Results Webcast and Conference Call

PR Newswire March 13, 2014

Xencor to Present at 2014 Leerink Global Healthcare Conference

PR Newswire February 6, 2014

Xencor, Inc. Announces Closing of Initial Public Offering

PR Newswire December 6, 2013

Xencor Prices Initial Public Offering

PR Newswire December 3, 2013